GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MEX:REGN) » Definitions » Shiller PE Ratio

Regeneron Pharmaceuticals (MEX:REGN) Shiller PE Ratio : 17.34 (As of May. 05, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Regeneron Pharmaceuticals Shiller PE Ratio?

As of today (2025-05-05), Regeneron Pharmaceuticals's current share price is MXN11620.03. Regeneron Pharmaceuticals's E10 for the quarter that ended in Mar. 2025 was MXN670.24. Regeneron Pharmaceuticals's Shiller PE Ratio for today is 17.34.

The historical rank and industry rank for Regeneron Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

MEX:REGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.96   Med: 51.51   Max: 2074.62
Current: 18.54

During the past years, Regeneron Pharmaceuticals's highest Shiller PE Ratio was 2074.62. The lowest was 16.96. And the median was 51.51.

MEX:REGN's Shiller PE Ratio is ranked better than
77.55% of 147 companies
in the Biotechnology industry
Industry Median: 32.73 vs MEX:REGN: 18.54

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2025 was MXN148.731. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is MXN670.24 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Regeneron Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Shiller PE Ratio Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.17 32.61 30.55 32.06 22.53

Regeneron Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.84 35.34 34.02 22.53 19.41

Competitive Comparison of Regeneron Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Regeneron Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regeneron Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=11620.03/670.24
=17.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=148.731/134.9266*134.9266
=148.731

Current CPI (Mar. 2025) = 134.9266.

Regeneron Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 26.516 100.684 35.534
201509 30.754 100.392 41.334
201512 23.041 99.792 31.153
201603 27.370 100.470 36.757
201606 31.254 101.688 41.470
201609 43.892 101.861 58.140
201612 45.151 101.863 59.807
201703 40.671 102.862 53.349
201706 60.374 103.349 78.821
201709 60.251 104.136 78.066
201712 29.459 104.011 38.215
201803 75.577 105.290 96.851
201806 94.711 106.317 120.198
201809 96.705 106.507 122.509
201812 140.390 105.998 178.705
201903 77.398 107.251 97.371
201906 32.271 108.070 40.291
201909 115.688 108.329 144.092
201912 130.700 108.420 162.653
202003 127.323 108.902 157.750
202006 175.655 108.767 217.901
202009 163.252 109.815 200.583
202012 203.694 109.897 250.087
202103 206.250 111.754 249.016
202106 556.771 114.631 655.346
202109 294.653 115.734 343.516
202112 403.921 117.630 463.316
202203 171.434 121.301 190.691
202206 150.281 125.017 162.193
202209 234.541 125.227 252.709
202212 204.708 125.222 220.573
202303 129.239 127.348 136.930
202306 145.723 128.729 152.739
202309 154.854 129.860 160.896
202312 172.968 129.419 180.328
202403 104.059 131.776 106.547
202406 227.352 132.554 231.422
202409 227.226 133.029 230.467
202412 168.097 133.157 170.331
202503 148.731 134.927 148.731

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (MEX:REGN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regeneron Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

From GuruFocus